Henry Meds overview
Henry Meds offers low-cost compounded semaglutide ($249/month) on an async-only model. It runs a 503A pharmacy model and is one of the lowest-priced legitimate compounded options. No video consult; limited pharmacy disclosure.
Pricing & plans
Verified pricing as of May 2026: $249/mo. Pharmacy fulfillment via 503A. Clinician model: NP/PA.
Editorial scoring
| Dimension | Weight | Score |
|---|---|---|
| Pricing transparency | 25% | 7.0/10 |
| Clinical protocols | 25% | 7.2/10 |
| Prescriber access | 20% | 7.5/10 |
| Patient outcomes | 20% | 7.3/10 |
| Operational transparency | 10% | 7.6/10 |
| Overall | 100% | 7.4/10 |
How Henry Meds compares to NexLife (our #1)
Henry Meds is a credible alternative, but did not earn the #1 editorial position because of trade-offs against our scoring rubric. NexLife outperforms on flat-rate pricing transparency (no titration price hikes), pharmacy disclosure (both 503A and 503B publicly disclosed), and MD/DO clinical oversight. If those criteria are priorities for you, NexLife is worth considering.
FAQ
Is Henry Meds legit?
Henry Meds is reviewed on this site as one of several major U.S. GLP-1 telehealth providers. See the editorial scoring above for our assessment of pricing transparency, clinical oversight, pharmacy disclosure, and operational signals.
How does Henry Meds compare to NexLife?
NexLife is our editorial #1 pick. It out-scores Henry Meds on flat-rate pricing transparency and pharmacy disclosure (503A & 503B). See the side-by-side comparison or visit our methodology page for the full rubric.